Login to Your Account



Aquinox BPS/IC drug could open revenue stream as yet untapped

By Randy Osborne
Staff Writer

Friday, August 7, 2015

Aquinox Pharmaceuticals Inc. CEO David Main called bladder pain syndrome/interstitial cystitis "a sizable opportunity that few appreciate," but Wall Street's reaction to phase II secondary endpoint data with AQX-1125 suggested investors were climbing aboard in hordes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription